Clinical Trial Detail

NCT ID NCT04382664
Title UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ultimovacs ASA
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Ipilimumab + Nivolumab + Sargramostim + UV1 Telomerase peptide vaccine

Age Groups: adult senior

No variant requirements are available.